Papers/PMID:36209091
Evaluation of therapeutic effects of crocin in attenuating the progression of diabetic nephropathy: a preliminary randomized triple-blind placebo-controlled trial.
BMC complementary medicine and therapies2022The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
crocin-1 — decreases triglycerides
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“As listed in Table 2, comparison of the crocin and placebo groups for changes in variables (before- after) showed that mean serum TG levels decreased significantly in the crocin group compared with the increasing values in the placebo group (P-Value = 0.03).”
Quoted verbatim from Evaluation of therapeutic effects of crocin in attenuating the progression of diabetic nephropathy: a preliminary randomized triple-blind placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 15 mg crocin tablet daily
- Population
- Adults with type 2 diabetes and microalbuminuria on routine antidiabetic, antihypertensive and lipid-lowering care; crocin 15 mg/day versus placebo
Evaluation of therapeutic effects of crocin in attenuating the progression of diabetic nephropathy: a preliminary randomized triple-blind placebo-controlled trial.2022PMID:36209091Permalink